Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01178 (oxytocin)
 15,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An abortion interval time of 15.9 hours was achieved in a group of women treated in midtrimester with intra-amniotic prostaglandin F2alpha and intravenous oxytocin. Routine addition of intracervical laminaria to this regimen was not helpful. The most useful prostaglandin protocol seems to be 30 mg as an initial dose followed by a booster at six hours.
 ...
PMID:Intra-amniotic prostaglandin F 2alpha as a midtrimester abortifacient: effect of oxytocin and laminaria. 111 59

Seventy-four patients, from 16 to 20 weeks pregnant, received intra-amniotic urea (80 Gm.) and intravenous oxytocin for the purpose of inducing abortion. Seventy-one of the 74 patients were successfully aborted by the primary method with a mean injection-to-abortion interval of 18.33 hours. There were no serious side effects, and the mean hospital stay was 32 hours. Following urea injection, the mean serum urea nitrogen rose to 33 mg. per cent at 4 hours. Maximum changes in serum electrolytes occurred at 8 to 12 hours after injection and included a decrease in the mean concentrations of sodium, chloride, and carbon dioxide and an increase in serum potassium. An increase in the urinary excretion of urea began within 4 hours, but significant diuresis did not occur in the presence of intravenous oxytocin administration. There was a significant increase in the leukocyte concentration while hematocrit values remained unchanged. Beginning approximately 8 hours following urea injection, the mean plasma fibinogen concentrations decreased by approximately 15 per cent and the mean platelet count showed a drop of approximately 18 per cent. Fibrinogen-fibrin degradation products were significantly increased in 36 per cent of the patients studied.
 ...
PMID:Intra-amniotic urea as a midtrimester abortifacient: clinical results and serum and urinary changes. 111 18

Among 4,069 healthy gravidas undergoing saline abortion, patients administered intravenous oxytocin had a significantly shorter instillation-to-abortion time (median, 25.5 hours) than did patients not administered oxytocin (median 33.3 hours). The instillation-to-abortion time was independent of the rate of oxytocin administration, which ranged from 1 to 4 U. per hour (17 to 67 mU. per minute), but was associated with the time at which oxytocin infusion was begun. When oxytocin infusion was started within eight hours after instillation, a shortened time from instillation to abortion was observed. Although oxytocin augmentation may result in a lower proportion of patients being exposed to the risk of infection associated with prolonged intervals from instillation to abortion, this potential advantage appears counterbalanced by an increased incidence of clinical consumptive coagulopathy associated with instillation-to-abortion intervals of less than 24 hours.
 ...
PMID:Oxytocin administration, instillation-to-abortion time, and morbidity associated with saline instillation. 111 83

Because it has been suggested that induction of labor results in increased perinatal mortality, 1972-1974 statistics from the Maternity Unit, Watford, England, General Hospital, are presented. Perinatal mortality was reduced from 22/1000 in 1972 to 11/1000 in 1974 while the induction of labor rate increased from 28% to 55%. 4 major contributory factors for the fall in perinatal mortality are noted: 1) 70% of all the patients in the unit have continuous fetal heart rate monitoring; 2) the cervix of all patients whose previous pregnancy was terminated is examined at each visit, and when there is early dilatation or effacement of the cervix, cervical circumsuture is inserted; 3) amniocentesis is performed on at risk patients, and abortion may be performed in some cases where there would have otherwise been a stillbirth; and 4) there has not been an increased number of premature babies or of operative deliveries because of precautions taken, and the use of oxytocin has resulted in short labors and healthy babies. It is suggested that obstetric units in Britain publish their perinatal mortality figures and their induction of labor rates along with the units' policies concerning fetal monitoring and the use of ultrasound confirmation of dates.
 ...
PMID:Letter: Induction of labour and perinatal mortality. 111 35

This study determines whether induction of second trimester abortions with intraamniotic prostaglandin F2alpha (PgF2a) could be facilitated by use of intravenous oxytocin, and whether side effects of prostaglandin administration could be minimized by using lower doses of prostaglandin in conjunction with oxytocin. 26 healthy pregnant females aged 16 to 39 years (16 to 26 weeks gestation) were divided into 2 groups: group 1 consisting of 12 patients who had intraamniotic injection of PGF2a 25 mg. followed by additional doses of 5 to 25 mg. injected at intervals of 8 to 10 hours (mean dose, 40.2 mg.), and group 2, consisting of 14 patients who had intravenous infusion of oxytocin 2 hours after intraamniotic injection of 25 mg. PGF2a (mean dose, 28.2 hours). 9 out of 12 patients in group 1 aborted within 36 hours (mean abortion time, 24 hours and 41 minutes) while all patients in group 2 aborted within 28 hours (mean abortion time, 15 hours and 37 minutes). Nausea, vomiting, and diarrhea occured in 9 group 1 patients while 2 patients in group vomited. There were no significant changes in blood pressure, heart rate, respiration or metabolic parameters. This study shows that under carefully controlled conditions, administration of intravenous infusion of oxytocin following intraamniotic administration of PgF2a shortens injection to abortion time.
 ...
PMID:Mid-trimester abortion with intra-amniotic prostaglandin F2 alpha and intravenous oxytocin infusion. 113 39

It has been reported that intra-amniotic administration of 15-methyl PGF2a (prostaglandin F2alpha) for abortion results in a high level of uterine contractility, a high rate of success, and a low incidence of side effects. This study assesses the abortifacient activity of 15-methyl PGF2alpha administered intramuscularly in 80 healthy women aged 14 to 40 with gestational ages between 8 and 22 weeks. 56 patients were nulliparious. Transabdominal intra-amniotic pressure monitoring was used to measure uterine contractility and to establish an effective dose schedule. 350 to 520 mcg of 15-methyl PGF2a were administered intramuscularly at 2-hour intervals until the onset of abortion. Intravenous oxytocin was infused in 6 cases to facilitate passage of retained placental tissue. Medications were given to reduce diarrhea, vomiting, and pain. All patients aborted. Total drug dose ranged from 900 to 8400 mcg; mean dose was 3254.32 mcg. Duration of treatment ranged from 4 to 34 hours. Induction-abortion time ranged from 5.5 to 35 hours, with mean interval of 15.70 hours. 89% of the patients experienced gastrointestinal side effects. 14 patients had temperature elevation more than or equal to 100.6 degrees F. There were no significant complications. The 15-methyl PGF2a patients were matched with 80 gravidas who had abortion using PGE2 20 mg vaginal suppositories. There were no statistical differences in interval to abortion between the 2 groups.
 ...
PMID:Interruption of pregnancy by prostaglandin 15-methyl F2alpha. 114

Prostaglandin F2alpha administered by continuous transcervical extra-amniotic infusion, and supplemented with oxytocin, given intravenously, to induce therapeutic abortion during the second trimester in 50 cases. This method was successful in all cases and has the advantages of being technically simple and requiring only a small dose of prostaglandin. The main hazard is intrauterine infection, which can be prevented by preliminary bacteriological investigation of the cervix and appropriate prophylactic antibiotic therapy. Prostaglandins are not yet available in Australia for general medical use. Our experience with prostaglandin F2alpha administered in the manner described indicates that it has an important part to play in gynaecological therapy.
 ...
PMID:Prostaglandin F2alpha given by continuous transcervical extra-amniotic infusion combined with intravenous oxytocin infusion for therapeutic termination of mid-trimester pregnancies. 115 99

Midtrimester abortion was accomplished in 75 patients by the intraamniotic instillation of 80 g of urea and the intravenous administration of oxytocin. In 33 of the patients, laminaria tents were inserted into the cervix. No severe complication occurred; all fetuses were stillborn. A single urea instillation was effective in 94.6% of the patients. The mean instillation-abortion interval was significantly (p less than 0.02) shorter in patients with laminaria tents than in those without. The tents probably prevent cervical rupture in s-me patients. Significant but transient changes occurred in platelet count and blood urea nitrogen one hour after urea instillation. Surgical removal of the placenta was required in 18.7% of the 75 patients; infection occurred in 2.6%. The combined use of urea, oxytocin, and laminaria appears to be an effective and relatively safe method of inducing abortion during the second trimester.
 ...
PMID:Induction of midtrimester abortion with intraamniotic urea, intravenous oxytocin and laminaria. 119 62

Schulman et al reported reduction in interval-abortion time and decreased side effects when prostaglandin (PG) E2 vaginal suppositories were administered within a contraceptive diaphragm. The authors conducted a study to confirm Schulman et al' finding. 2 groups of 20 patients with gestational ages ranging from 13 to 20 weeks were matched. 1 group (non-diaphragm) had a 20 mg. suppository inserted every 4 hours high in the vaginal fornix. The other group (diaphragm) had a contraceptive diaphragm containing the suppository inserted at 4-hour intervals. The authors' protocol differed from that of Schulman's in that oxytocin sensitivity was not sought and PGE2 alone was used. Oxytocin, however, was used to promote placental expulsion following fetal delivery in 4 cases. There were no statistically significant differences observed between the groups with respect to total drug dose (84 mg. for diaphragm group and 80 mg. for non-diaphragm), abortion-interval time (15.2 hours vs. 14.3 respectively), or frequency of side effects (vomiting, diarrhea). Schulman's reduced side effects may have followed the decreased absorption rate of PGE2 and avoidance of plasma peaks secondary to reduction in drug-mucosal interface. Schulman also reported onset of uterine activity in the diaphragm group (mean, 41 minutes) versus the control group's mean of 79.4 minutes. There is no known physiologic explanation for such findings.
 ...
PMID:Letter: PGE2 as a vaginal abortifacient - diaphragm effect. 119 86

Abortion was successfully induced in 62 of 68 patients in the 9th to the 26th week of pregnancy be serial intramuscular administration of 15(S)-15-methyl-prostaglandin F2alpha (15-ME-PGF2alpha). In 6 patients who failed to abort after 24 hours of prostaglandin administration, a concomitant infusion of oxytocin was initiated; 5 of these patients aborted within 12 hours of the combined therapy. A single patient failed to abort, even with the combined therapy, and underwent surgical evacuation. The mean abortion time in the 67 successful inductions was 14.56 hours. Parous patients aborted somewhat fasteter, mean 13.98 hours, as compared to nulliparous patients, mean 15.02 hours, but this difference was not statistically significant. In this study initial intramuscular injection of 100 mug 15-ME-PGF2alpha was followed in 1 hour by 250 mug and then 250 mug every 2 hours with concomitant oxytocin therapy initiated after 24 hours. The results with this dose schedule were compared to the results obtained in a previous study with a higher dose schedule, an initial dose of 100 mug 15-ME-PGF2alpha, followed in 1 hour by 250 mug then 500 mug every 2 hours. There was significant difference in the mean abortion time and the incidence of side effects between the 2 dose schedules. The mean abortion time for patients with gestational ages 16 weeks and less was the same with both dose schedules, however patients with gestational ages of 17 weeks and higher aborted somewhat faster with the higher dose schedule. It might therefore be advisable for patients with gestations of 17 weeks and higher to be treated with the higher dose schedule. In earlier gestations patients could be started on the lower schedule, and if abortion had not occurred within 15 hours the dose of 15-ME-PGF2alpha could then be increased to 500 mug every 2 hours.
 ...
PMID:Serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha in the induction of abortion. 120 81


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>